The treatment of chronic, non-healing wounds is one of the biggest challenges faced by healthcare providers (Irving, 2019), costing the NHS £5.3 billion per annum (Guest et al, 2015). PROMOGRAN™ Matrix and PROMOGRAN PRISMA™ Matrix have been shown to help stimulate healing and reduce the risk of a wound becoming hard-to-heal. A working group of key opinion leaders met in June 2019 to discuss the use of PROMOGRAN™ Matrix and PROMOGRAN PRISMA™ Matrix to kick-start the treatment of chronic wounds, and to develop a decision pathway for clinical practice to support clinicians. The group’s recommendations on appropriate use are presented here.